Data/Analytics

Sharecare scales up again with QualityHealth buy

Sharecare scales up again with QualityHealth buy

Complementary solutions to drive growth with health plans as well as pharma clients, companies say.

Health providers are embracing value-based care: survey

Health providers are embracing value-based care: survey

Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.

Demand for Harvoni limited by insurance reimbursement: KOLs

An arduous reimbursement process has put a damper on how quickly patients can receive the drug, say analysts, citing KOLs.

Five things for pharma marketers to know: Tuesday, November 12

Five things for pharma marketers to know: Tuesday, November 12

Life expectancy for patients cured of advanced HCV similar to healthy peers: study; Ackman takes a $2 billion stake in animal drugmaker Zoetis; Amgen and AstraZeneca report that brodalumab bested Stelara in psoriasis head-to-head.

HHS dials back ACA enrollment forecast

The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.

Five things for pharma marketers to know: Tuesday, November 11

Five things for pharma marketers to know: Tuesday, November 11

FDA will evaluate effect of pharma commercial barrage; Pfizer settles Neurontin marketing lawsuit for $321 million; AbbVie and Gilead release top-line results on HCV combo therapies.

Finding value in generic drugs with a twist

Finding value in generic drugs with a twist

Developing exclusive features from proven generics is a growing opportunity for patients as much as it is a ploy for life-cycle extension.

Pradaxa bleeding episodes no different than warfarin: study

An FDA study of Medicare patients found that patients who took Pradaxa showed a reduced risk of stroke and brain hemorrhage.

UK docs against new statin guidelines

According to a survey, general practitioners are against new NHS guidelines on prescribing statins.

Orphan drugs a niche no longer

Orphan drugs a niche no longer

Orphan drug growth will easily outpace non-orphans through 2020.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.